Novel therapies for thyroid cancer

Area of Science:

• Oncology
• Pharmacology
• Endocrinology

Background:

• Tyrosine kinases play a crucial role in thyroid carcinoma pathogenesis.
• New therapeutic options, including tyrosine kinase inhibitors (TKIs), are emerging for differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC).
• Vandetanib and cabozantinib are approved for advanced MTC, while sorafenib treats late-stage DTC.

Purpose of the Study:

• To review the efficacy and adverse effects of newly approved tyrosine kinase inhibitors (TKIs) for advanced thyroid cancer.
• To highlight the need for comparative studies and evidence-based guidelines for TKI selection in thyroid cancer treatment.

Main Methods:

• Review of Phase III studies demonstrating the efficacy of TKIs compared to placebo.
• Analysis of common adverse reactions associated with VEGFR blockade and TKI therapy.
• Identification of frequent side effects including hypertension, proteinuria, fatigue, gastrointestinal disturbances, and TSH increase.

Main Results:

• Vandetanib, cabozantinib, and sorafenib significantly prolonged progression-free survival in advanced MTC and DTC, respectively.
• Common adverse reactions include hypertension, proteinuria, impaired wound healing, hemorrhage, thrombosis, congestive heart failure, fatigue, and gastrointestinal issues.
• Increased thyroid-stimulating hormone (TSH) is a frequent TKI side effect due to pituitary T3 and T4 uptake inhibition.

Conclusions:

• Direct comparative data on treatment outcomes and toxicity between different TKIs are currently lacking.
• Evidence-based medicine guidelines are essential for guiding the selection of the most effective and least toxic TKI and determining optimal treatment timing.